Kidney transplantation is a well-established therapy for patients with end-stage renal disease. While a significant improvement of short-term results has been achieved in the short-term, similar results were not reported in the long-term. Heme-oxygenase (HO) is the rate-limiting enzyme in heme catabolism, converting heme to iron, carbon monoxide, and biliverdin. Heme-oxygenase overexpression may be observed in all phases of transplant processes, including brain death, recipient management, and acute and chronic rejection. HO induction has been proved to provide a significant reduction of inflammatory response and a reduction of ischemia and reperfusion injury in organ transplantation, as well as providing a reduction of incidence of acute rejection. In this review, we will summarize data on HO and kidney transplantation, suggesting possible clinical applications in the near future to improve the long-term outcomes.

中文翻译：

---

血红素氧合酶和肾脏移植：靶向治疗的潜力？

肾脏移植是终末期肾脏疾病患者的公认疗法。虽然短期内取得了短期结果的显着改善，但长期未见类似结果。血红素加氧酶（HO）是血红素分解代谢中的限速酶，可将血红素转化为铁，一氧化碳和胆绿素。血红素加氧酶的过度表达可能出现在移植过程的所有阶段，包括脑死亡，接受者管理以及急性和慢性排斥反应。已经证明HO诱导可以显着减少器官移植中的炎症反应并减少局部缺血和再灌注损伤，并且可以减少急性排斥反应的发生。在这篇评论中，我们将总结有关HO和肾脏移植的数据，